Filing Flows › BioXcel Therapeutics (BTAIQ) › Q1 2026 › vs Q4 2025
BioXcel Therapeutics (BTAIQ) Q1 2026 vs Q4 2025 (quarter over quarter)
BioXcel Therapeutics's revenue fell $50K (-20%) from $256K in Q4 2025 to $206K in Q1 2026.
BioXcel Therapeutics, Q1 2026: revenue $206K (+23% year over year), net loss $12.7M, operating cash flow −$11.8M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $206K | $256K | −$50K | -20% |
| Net loss | $12.7M | $12.5M | $146K | +1% |
| Costs & expenses | $12.9M | $12.8M | $96K | +0.7% |
| Operating costs | $10.4M | $10.5M | −$109K | -1% |
| Interest & other, net | $2.5M | $2.3M | $205K | +9% |
| Cost of revenue | $283K | $32K | $251K | +784% |
| Research & development | $3.0M | $6.7M | −$3.7M | -56% |
| SG&A | $7.2M | $3.8M | $3.4M | +89% |
| Operating cash sources | $12.7M | $12.5M | $146K | +1% |
| Depreciation | $58K | $74K | −$16K | -22% |
| Share-based compensation | $435K | $450K | −$15K | -3% |
| Working capital & other | $389K | −$2.2M | $2.6M | — |
| Cash used in operations | $11.8M | $14.2M | −$2.4M | -17% |
| Net loss absorbed | $12.7M | $12.5M | $146K | +1% |
Questions
How much did BioXcel Therapeutics's revenue grow quarter over quarter in Q1 2026?
BioXcel Therapeutics's revenue fell $50K (-20%) from $256K in Q4 2025 to $206K in Q1 2026.